文献速递神经核医学

18F-DOPA与18F-DTBZ用于特发性帕金森病PET/CT显像的比较

Comparison of 18 F-DOPA and 18 F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease.
PubMed 文献 · Clin Nucl Med · 2022-08-16

研究纳入32例帕金森病患者和12例健康对照,所有受试者均行18F-DOPA与18F-DTBZ PET/CT,采用视觉分析和半定量分析(特异性摄取比值SUR)。结果显示两种示踪剂纹状体SUR呈线性相关(P<0.05),早期患者纹状体SUR下降百分比无统计学差异(配对t检验,P>0.05),视觉分析结果一致。

要点

  • 32例帕金森病患者与12例健康对照均行18F-DOPA和18F-DTBZ PET/CT。
  • 两种示踪剂纹状体SUR呈线性相关(P<0.05)。
  • 早期患者两种示踪剂纹状体SUR下降百分比无统计学差异(P>0.05)。

核心结论

  • 18F-DTBZ与18F-DOPA可反映早期帕金森病相同水平的多巴胺能神经元变性,且两者视觉分析结果一致。

研究设计与样本

  • 研究纳入32例帕金森病患者和12例健康对照,所有受试者均行18F-DOPA与18F-DTBZ PET/CT,结果采用视觉分析和半定量分析(特异性摄取比值SUR)判读。

主要发现

  • 帕金森病患者中Hoehn-Yahr I期7例、II期14例、III期11例。
  • 两种示踪剂纹状体SUR之间呈线性相关(P<0.05)。
  • 早期患者中两种示踪剂纹状体SUR下降百分比无统计学差异(配对t检验,P>0.05)。
  • 初始视觉分析中,18F-DTBZ判定所有患者均为阳性(单侧6例、双侧26例),18F-DOPA判定31例为阳性(单侧8例、双侧23例)。
  • 以健康对照壳核SUR(SURT)设定SUR图像上限后,两种示踪剂均判定所有患者为阳性(18F-DTBZ:单侧5例、双侧27例;18F-DOPA:单侧4例、双侧28例)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare 2 imaging tracers, 18 F-DOPA and 18 F-DTBZ, for PET/CT imaging in idiopathic Parkinson disease (PD). METHODS: We recruited 32 PD patients and 12 healthy controls in this study. All subjects underwent both 18 F-DOPA and 18 F-DTBZ PET/CT, and the results were interpreted by visual analysis and semiquantitative analysis (specific uptake ratios [SURs]). A 1-way analysis of variance was used to compare the clinical data and the SURs among the patients at different stages. Regression analysis was performed to analyze the correlation between the SURs and the clinical data. RESULTS: Among the PD patients, there were 7 patients in Hoehn and Yahr stage I, 14 patients in stage II, and 11 patients in stage III. Linear correlation was found in striatal SURs between the 2 tracers ( P < 0.05). In patients of early stages, the striatal SUR decrease percent of 2 tracers had no statistical difference (paired t test, P > 0.05). By initial visual analysis, all the patients were interpreted as positive with 18 F-DBTZ (6 unilaterally, 26 bilaterally), and 31 cases were regarded as positive with 18 F-DOPA (8 unilaterally, 23 bilaterally). After setting the upper limit of SUR images with the putamen SURs of healthy controls (SUR T ), all patients were interpreted as positive with both tracers ( 18 F-DTBZ: 5 unilaterally, 27 bilaterally; 18 F-DOPA: 4 unilaterally, 28 bilaterally). CONCLUSION: 18 F-DTBZ and 18 F-DOPA could reflect the same level of dopaminergic neuron degeneration for PD in early stages, and they have the consistent visual analysis results.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shi X, Yang Y, Jiang L, et al. Comparison of 18 F-DOPA and 18 F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease. Clin Nucl Med. 2022. PMID: 35961651. doi:10.1097/RLU.0000000000004361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。